It is established that the mechanism for the initiation and/or regression of myocardial hypertrophy cannot be fully explained by blood pressure control alone. We have shown the evidence for the existence of factor (s) other than blood pressure control that are responsible for an increase in myocardial growth. The hypothesis we want to examine is that development of hypertrophy is initiated by a signal (mechanical or humoral) to the myocardium, which in turn produces a soluble factor that is responsible for triggering protein synthesis and myocardial cell growth. We have identified a soluble factor in the hypertrophied myocardium of spontaneously hypertensive rats (SHR) using myocytes as our bioassay system. The factor has been purified to its homogeneity and partially sequenced. It is a novel peptide with a molecular weight of 12,500 daltons. We have named this factor myotrophin. Recently, we have completed purification and partial sequencing of myotrophin from human cardiomyopathic heart. When myotrophin was added to neonatal cells in culture, the cells showed an enlargement in size that corresponds to a dose-dependent fashion. Furthermore, myotrophin caused a four-fold increased in connexin (gap junction protein) nd a two-fold increase in the total myosin transcript level, associated wit ha selective increase in beta myosin heavy chain expression. At the EM level, myotrophin causes accelerated organization and maturation of the myofibril within 48 hrs. after its addition. More importantly, we have raised specific antibodies against myotrophin and developed a bot blot assay to quantify myotrophin. Our preliminary data showed that myotrophin concentration is increased significantly in the hypertrophied ventricles of SHR and cardiomyopathic human compared to that in normals. Thus suggested that myotrophin may be an important factor in the hypertrophying process. Furthermore, we have isolated a partial cDNA clone for myotrophin and by using a specific probe (RMyo69A), the myotrophin mRNA size was found to be 6 Kb. Our goal for the next five years is to complete the sequencing of and to fully characterized myotrophin, quantity myotrophin (mRNA and protein) in the heart and other tissues during growth and evolution of hypertrophy in SHR and normal pathophysiological significance by determine its role in the initiation and development of cardiac myotrophin may play an important role in the development of hypertrophy. The proposed experiments will demonstrate that myotrophin may be controlling key for the development of cardiac hypertrophy. Continued research may yield information on the mechanism which translates cardiac load and myocardial stress into biochemical messages leading to protein synthesis. Demonstrating the role of myotrophin in initiating myocardial hypertrophy will help in the therapeutic planning for patients with hypertensive heart disease, especially in the development of an appropriate antagonist.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL047794-01A3
Application #
2223881
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1993-12-01
Project End
1996-11-30
Budget Start
1993-12-01
Budget End
1994-11-30
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Vasudevan, Neelakantan T; Mohan, Maradumane L; Gupta, Manveen K et al. (2013) G??-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor ?-induced cardiac ?-adrenergic receptor dysfunction. Circulation 128:377-87
Das, Biswajit; Young, David; Vasanji, Amit et al. (2010) Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc Res 87:524-34
Gupta, Anasuya; Gupta, Sudhiranjan; Young, David et al. (2010) Impairment of ultrastructure and cytoskeleton during progression of cardiac hypertrophy to heart failure. Lab Invest 90:520-30
Gupta, Sudhiranjan; Maitra, Ratan; Young, Dave et al. (2009) Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy. Am J Physiol Heart Circ Physiol 297:H627-36
Sivakumar, P; Gupta, Sudhiranjan; Sarkar, Sagartirtha et al. (2008) Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 307:159-67
Gupta, Sudhiranjan; Young, David; Maitra, Ratan K et al. (2008) Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 375:637-49
Das, Biswajit; Gupta, Sudhiranjan; Vasanji, Amit et al. (2008) Nuclear co-translocation of myotrophin and p65 stimulates myocyte growth. Regulation by myotrophin hairpin loops. J Biol Chem 283:27947-56
Gupta, Sudhiranjan; Sen, Subha (2005) Role of the NF-kappaB signaling cascade and NF-kappaB-targeted genes in failing human hearts. J Mol Med 83:993-1004
Adhikary, Gautam; Gupta, Sudhiranjan; Sil, Parames et al. (2005) Characterization and functional significance of myotrophin: a gene with multiple transcripts. Gene 353:31-40
Gupta, Sudhiranjan; Young, David; Sen, Subha (2005) Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289:H20-9

Showing the most recent 10 out of 19 publications